What Is a Normal LDL Level?: A Functional-Medicine Interpretation Guide

What Is a Normal LDL Level? A Functional-Medicine Interpretation Guide

Most people glance at their cholesterol panel, see a number in the 'normal' column, and breathe a sigh of relief. But if you ask a functional-medicine practitioner the same question — what is a normal LDL level? — the answer is considerably more nuanced. Standard laboratory reference ranges are built around population averages, not optimal health. They are designed to identify disease, not prevent it. The result is that millions of people are told their lipids are fine while measurable cardiovascular risk continues to build silently.

This guide unpacks what 'normal' actually means for LDL cholesterol, LDL particle number, homocysteine, and fibrinogen — four of the most clinically relevant biomarkers for cardiovascular risk assessment — and explains why the gap between a lab's reference range and a truly optimal value matters more than most physicians have time to discuss during a 15-minute appointment.

---

What Is a Normal LDL Cholesterol Level?

The conventional answer depends on your risk category. Most clinical guidelines, including those from the American Heart Association and the American College of Cardiology, define LDL thresholds as follows:

These numbers come from decades of statin trials and epidemiological data. But functional medicine places a heavier emphasis on context: a person with an LDL of 115 mg/dL and predominantly large, buoyant LDL particles, optimal HDL, low triglycerides, and no inflammation may carry far less actual risk than someone with an LDL of 95 mg/dL composed mostly of small, dense particles alongside elevated C-reactive protein.

The landmark INTERHEART study, which enrolled over 15,000 cases across 52 countries, confirmed that non-HDL cholesterol and the apoB/apoA1 ratio were stronger predictors of myocardial infarction than LDL-C alone (Yusuf et al., The Lancet 2004; PMID: 15364185). This is part of why forward-thinking clinicians increasingly ask for particle-level data rather than stopping at the standard lipid panel.

---

What Is a Normal LDL Particle Number Level?

LDL particle number (LDL-P) and the related marker apolipoprotein B (apoB) are arguably more predictive of cardiovascular events than LDL cholesterol by itself. Here is why: each LDL particle carries exactly one apoB molecule. It is not the cholesterol cargo inside the particle that causes arterial damage — it is the particle's ability to penetrate the endothelium and trigger inflammation. More particles mean more opportunities for penetration, even if each individual particle carries less cholesterol.

This phenomenon is called LDL discordance. A patient with an LDL-C of 100 mg/dL might have an LDL-P of 800 nmol/L (low risk) or 1,600 nmol/L (high risk), depending on particle size distribution. The Atherosclerosis Risk in Communities (ARIC) study demonstrated that LDL-P predicted coronary heart disease events more accurately than LDL-C in multivariate analysis (Hoogeveen et al., Journal of Clinical Lipidology 2014; PMID: 24793441).

Optimal and reference ranges for LDL-P vary slightly by laboratory, but a general clinical framework looks like this:

For apoB — the more widely available proxy for LDL-P — most functional practitioners aim for values below 80 mg/dL in moderate-risk individuals and below 65–70 mg/dL in higher-risk patients, compared to most labs' standard 'normal' cutoff of < 130 mg/dL, which is clearly too permissive from a prevention standpoint.

If you have access to advanced lipid testing through a platform like Function Health or a direct-to-consumer lab panel, requesting an NMR LipoProfle or an apoB alongside your standard lipid panel is one of the highest-leverage upgrades you can make to your cardiovascular risk assessment.

---

What Is a Normal Homocysteine Level?

Homocysteine is an amino acid produced during the metabolism of methionine. Elevated homocysteine — a condition called hyperhomocysteinemia — is an independent risk factor for cardiovascular disease, stroke, and cognitive decline. It damages the endothelium, promotes oxidative stress, and impairs nitric oxide signaling, all of which accelerate atherosclerosis even when LDL is within a conventional normal range.

Standard laboratory 'normal' for homocysteine is typically listed as 5–15 µmol/L. Functional medicine narrows this considerably:

The primary drivers of elevated homocysteine are deficiencies in folate, vitamin B6, and vitamin B12 — all essential cofactors in the remethylation and transsulfuration pathways. The MTHFR gene variant (particularly C677T) can reduce methylation efficiency by 30–70%, making dietary folate less bioavailable and pushing homocysteine upward even in people who eat a 'balanced' diet.

A 2010 meta-analysis published in BMJ found that B-vitamin supplementation significantly reduced homocysteine levels, and studies targeting secondary stroke prevention showed meaningful risk reduction with combined B6, B12, and folate supplementation (Clarke et al., BMJ 2010; PMID: 20576740). Anyone with an LDL panel that looks fine but has ongoing vascular symptoms or a family history of early heart disease should ask their clinician specifically about homocysteine.

---

What Is a Normal Fibrinogen Level?

Fibrinogen is a clotting protein produced by the liver, and its elevation is both a marker of systemic inflammation and an independent cardiovascular risk factor. When fibrinogen is chronically elevated, blood viscosity increases, clot formation is more likely, and the inflammatory milieu of the arterial wall becomes more hostile.

Conventional labs typically flag fibrinogen as abnormal only above 400–500 mg/dL. Functional practitioners prefer to see it in the lower half of the reference range:

A landmark prospective study — the Fibrinogen Studies Collaboration — pooled individual participant data from 154,000 adults across 31 studies and found that elevated fibrinogen was associated with substantially increased risk of coronary heart disease, stroke, and all-cause mortality, independent of conventional risk factors (Fibrinogen Studies Collaboration, JAMA 2005; PMID: 15755945).

Fibrinogen rises with smoking, obesity, physical inactivity, chronic infections, and inflammatory conditions. Interventions that lower systemic inflammation — including Omega-3 fatty acids, aerobic exercise, dietary fiber, and addressing underlying infections — also tend to lower fibrinogen over time. If your LDL is in range but fibrinogen is persistently above 350 mg/dL, that combination may warrant a deeper clinical conversation.

For more on how inflammatory biomarkers interact with cardiovascular risk, the overview of high-sensitivity CRP and its role in heart health is a useful companion read.

---

Reading Your Lipid Panel Holistically: The Full Cardiovascular Picture

Functional medicine treats biomarkers as a constellation, not individual data points. When interpreting cardiovascular risk, a complete assessment might include:

1. LDL-C — the foundational cholesterol metric
2. LDL-P or apoB — particle burden, more predictive than LDL-C alone
3. HDL-C and HDL functionality — efflux capacity matters more than HDL number
4. Triglycerides — a proxy for insulin resistance and VLDL overproduction
5. Non-HDL cholesterol — (total cholesterol minus HDL); strong independent predictor
6. Homocysteine — methylation status and endothelial damage risk
7. Fibrinogen and hs-CRP — inflammatory load and clotting propensity
8. Fasting insulin and HbA1c — insulin resistance drives small, dense LDL particle formation
9. Lp(a) — genetically determined, elevated in ~20% of the population, significantly raises risk

A person can have a completely unremarkable lipid panel and still have three or four of these secondary markers pointing toward elevated risk. Conversely, someone with a mildly elevated LDL-C who scores optimally across all inflammatory and metabolic markers may have less actual arterial burden than their number suggests.

This is the core insight that platforms like Ones were built around: lab results don't exist in isolation, and a single biomarker — however important — is never the whole story.

---

What This Means for Your Formula

When Ones analyzes your lab work, it looks beyond LDL-C to assess particle-level risk, inflammatory burden, and the upstream metabolic drivers of dyslipidemia. Based on that analysis, relevant ingredients from Ones' catalog may be included at clinically validated doses.

Omega-3 (EPA/DHA): High-dose EPA and DHA have been shown in meta-analyses to reduce triglycerides by 20–30%, lower VLDL particle count, and modestly reduce fibrinogen and inflammatory markers. The REDUCE-IT trial demonstrated that 4g/day of icosapentaenoic acid (EPA) reduced major adverse cardiovascular events by 25% in high-risk patients already on statins (Bhatt et al., New England Journal of Medicine 2019; PMID: 30415628). Ones includes pharmaceutical-grade Omega-3 dosed to therapeutic EPA/DHA levels based on your triglyceride and inflammatory data.

Heart Support (Ones System Blend): This proprietary blend is formulated to support vascular health through ingredients with evidence for endothelial function, lipid metabolism, and inflammatory modulation — particularly relevant for users whose labs show discordant particle numbers or elevated fibrinogen alongside borderline LDL.

Vitamin D3 + K2 (MK-7): Vitamin D deficiency is associated with higher LDL and greater cardiovascular risk. K2 as MK-7 activates matrix Gla protein, which inhibits arterial calcification — a process that accelerates when LDL particles are trapped in the arterial wall. Ones includes D3 paired with K2 (MK-7) at doses calibrated to your measured 25-OH vitamin D levels, not a one-size-fits-all amount.

For context on how nutrient status interacts with lipid metabolism at a mechanistic level, the piece on how vitamin D deficiency affects cardiovascular markers goes deeper on this relationship.

If your homocysteine is elevated, Ones' AI will assess your B-vitamin inputs and may include activated B12 (methylcobalamin) and folate forms that bypass MTHFR inefficiencies — relevant because standard cyanocobalamin and folic acid are poorly utilized by individuals with common methylation variants.

---

Key Takeaways

• Standard LDL reference ranges are not the same as optimal ranges. Functional medicine targets LDL-C below 100 mg/dL (and often lower) for most adults, versus the conventional 'normal' cutoff of up to 130 mg/dL for low-risk individuals.
• LDL particle number (LDL-P) and apoB are more predictive of cardiovascular events than LDL-C alone. An optimal LDL-P is below 1,000 nmol/L; most standard panels don't measure this.
• Homocysteine above 10 µmol/L warrants investigation even though most labs call anything under 15 'normal.' B12, folate, and B6 status — and MTHFR genotype — are the primary drivers.
• Fibrinogen above 300–350 mg/dL signals elevated inflammatory and clotting risk independent of cholesterol. Omega-3s, exercise, and addressing root-cause inflammation are primary interventions.
• Cardiovascular risk is a multi-biomarker picture. LDL-C, apoB, homocysteine, fibrinogen, hs-CRP, fasting insulin, and Lp(a) together tell a far more complete story than any single number.
• Personalized supplementation based on your actual lab data — including high-dose Omega-3, D3+K2, and targeted B-vitamins — can meaningfully support cardiovascular biomarker optimization alongside lifestyle and dietary changes. Always consult a qualified healthcare provider before making changes to your treatment plan.